Iodixanol nasal solution reduces allergic rhinoconjunctivitis signs and symptoms in Allergen BioCube(®): a randomized clinical trial

PURPOSE: Allergic rhinitis (AR) affects ~20% of the population worldwide. The objectives of this study were to evaluate the safety and efficacy of iodixanol nasal solution (Nasapaque) for AR treatment, using the Allergen BioCube(®) (ABC(®)), an environmental exposure unit. Iodixanol is a commonly us...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomes, Paul J, Abelson, Mark B, Stein, Linda, Viirre, Erik, Villafranca, J Ernest, Lasser, Elliott C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400136/
https://www.ncbi.nlm.nih.gov/pubmed/30881050
http://dx.doi.org/10.2147/JAA.S150251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400136/
https://www.ncbi.nlm.nih.gov/pubmed/30881050
http://dx.doi.org/10.2147/JAA.S150251

Ejemplares similares